Major Depressive Disorder News and Research

RSS

Major Depressive Disorder (MDD) is a psychiatric condition characterized by depressed mood or anhedonia (significant loss of interest or pleasure). The condition affects more than 15.7 million adults and approximately 3 million adolescents (aged 13 to 17 years) in the USA each year.

Neurocrine Biosciences reports net loss of $29.3 million for fourth quarter 2015

Neurocrine Biosciences, Inc. today announced its financial results for the quarter and year ended December 31, 2015.

12 Feb 2016

Study: People with schizophrenia more likely to attempt suicide

A new study by the University of Toronto, released today, found that those with schizophrenia who'd been physically abused during childhood were five times more likely to have attempted suicide.

11 Feb 2016

FDA's PDAC supports use of Brintellix for treating cognitive dysfunction in adults with MDD

Takeda Pharmaceutical Company Limited and H. Lundbeck A/S today announced that the U.S. Food and Drug Administration’s Psychopharmacologic Drugs Advisory Committee voted 8 to 2 that the companies presented substantial evidence to support the effectiveness of Brintellix (vortioxetine) for treating certain aspects of cognitive dysfunction in adults with Major Depressive Disorder (MDD).

5 Feb 2016

Novel non-invasive method of vagus nerve stimulation reduces depressive symptoms

Researchers of a new study published in the current issue of Biological Psychiatry report successful reduction of depressive symptoms in patients using a novel non-invasive method of vagus nerve stimulation, or VNS.

5 Feb 2016

People injured by police officers more likely to have mental illness

People hospitalized due to an encounter with a law enforcement officer are more likely to have a mental illness, have longer hospitalizations, more injuries to the back and spine, and greater need for extended care than those hospitalized due to altercations with other civilians.

31 Jan 2016

Allergan's investigational medication rapastinel granted FDA Breakthrough Therapy designation

Allergan plc., a leading global pharmaceutical company today announced that its Phase III ready investigational medication rapastinel (GLYX-13) received Breakthrough Therapy designation from the U.S. Food and Drug Administration for adjunctive treatment of Major Depressive Disorder (MDD).

29 Jan 2016

Study provides better understanding of familial risk for depression

Building on a 30-year, three-generation study of depressed individuals, their children and offspring, a study published in the journal Psychiatry Research: Neuroimaging provides a better understanding of the familial risk for depression and the role neuroplasticity might have in increasing the risk of developing depression.

21 Jan 2016

Rapastinel demonstrates pro-cognitive benefits in animal model of cognitive impairment

Allergan plc, a leading global pharmaceutical company, announced today that new data on the investigational medication rapastinel (GLYX-13) and its lack of impairment on cognitive function were published in the peer-reviewed journal Behavioural Brain Research.

19 Jan 2016

Women who earn less than male counterparts more likely to experience depression, anxiety

The odds of major depressive disorder and generalized anxiety disorder were markedly greater among women who earned less than their male counterparts, with whom they were matched on education and years of experience, according to new research conducted at Columbia University's Mailman School of Public Health.

6 Jan 2016

Feeling sad can alter levels of inflammatory proteins linked to increased risk of comorbid diseases

Feeling sad can alter levels of stress-related opioids in the brain and increase levels of inflammatory proteins in the blood that are linked to increased risk of comorbid diseases including heart disease, stroke and metabolic syndrome, according to a study by researchers at The University of Texas Health Science Center at Houston.

17 Dec 2015

Cognitive behavioral therapy can be equally effective as second generation antidepressant for depression

Major depressive disorder affects more than 32 million Americans, and their first stop for treatment is often their primary care provider. A recent evidence review of several alternatives to medication found that using cognitive behavioral therapy as the first treatment for depression can be equally effective as using a second generation antidepressant.

10 Dec 2015

Novel antidepressant appears to be safe, effective against depression in clinical trial

A small clinical trial of a novel antidepressant that stimulates neurogenesis - the production of new brain cells - shows that the compound appears to be safe and may be effective against depression.

9 Dec 2015

New research finds insufficient evidence for use of Omega 3 supplements in treating major depressive disorder

New research out today concludes that there is insufficient evidence for the use of taking an Omega 3 fatty acid supplement in treating major depressive disorder.

5 Nov 2015

Estradiol fluctuation may enhance emotional sensitivity to psychosocial stress during menopausal transition

If you're feeling a little blue during the transition to menopause, there's good reason, according to a new study being reported online today in Menopause, the journal of The North American Menopause Society (NAMS). The study from the Department of Psychiatry at the University of North Carolina at Chapel Hill suggests that the estradiol (a form of estrogen) fluctuation that is common during the menopausal transition may enhance emotional sensitivity to psychosocial stress.

4 Nov 2015

New Rice University study explores connections between fatal bereavement and cardiovascular risk

Medical professionals know that when a spouse dies, the surviving partner is at increased risk of suffering early mortality - but they don't entirely understand why. A new Rice University professor has received a $3.765 million R01 grant from the National Institutes of Health to embark on a five-year study of the connection between psychological and physiological responses to such extraordinary stress.

27 Oct 2015

Neurocrine Biosciences announces positive data from NBI-98854 Phase III trial in tardive dyskinesia

Neurocrine Biosciences, Inc. announced today that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant reduction in tardive dyskinesia during the six weeks of placebo-controlled treatment in the Kinect 3 clinical trial. This Phase III trial included moderate to severe tardive dyskinesia patients with underlying schizophrenia, schizoaffective disorder, bipolar or major depressive disorder.

8 Oct 2015

FDA approves MagVenture MagVita TMS Therapy system for treatment of Major Depressive Disorder

On July 31, 2015 the US Food and Drug Administration cleared the MagVita TMS Therapy system for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.

28 Aug 2015

Physicians may now have tools to predict people at greater risk of attempting suicide

People being treated for bipolar disorder and other psychiatric illnesses are at greater risk of attempting suicide, but physicians may now have tools to predict which of those individuals will attempt it and intervene early to prevent such tragedies from occurring.

18 Aug 2015

Neurocrine completes enrollment in Phase III clinical trial of NBI-98854 in tardive dyskinesia patients

Neurocrine Biosciences, Inc. announced today that it has recently completed subject randomization of the Phase III clinical trial (Kinect 3 Study) of its proprietary Vesicular Mono-Amine Transporter 2 (VMAT2) compound NBI-98854 in tardive dyskinesia patients.

13 Aug 2015

Aerobic exercise can help reduce excessive daytime sleepiness among depressed people

Aerobic exercise can help alleviate excessive daytime sleepiness among depressed individuals, researchers with UT Southwestern Medical Center's Center for Depression Research and Clinical Care have found.

12 Aug 2015